Oriana Papin-Zoghbi, AOA Dx CEO

Ex­clu­sive: Liq­uid-biop­sy start­up clos­es $17M to fund ovar­i­an can­cer di­ag­nos­tic test

Liq­uid biop­sy start­up AOA Dx has col­lect­ed $17 mil­lion to sup­port the de­vel­op­ment of its di­ag­nos­tic test for ovar­i­an can­cer as well as the plat­form on which it is based.

The com­pa­ny’s di­ag­nos­tic plat­form, Gly­coLo­cate, is de­signed to de­tect cell sig­nal­ing mol­e­cules called gan­glio­sides in the blood. El­e­vat­ed lev­els are of­ten seen in can­cer pa­tients.

In Jan­u­ary, AOA Dx start­ed its prospec­tive study OVERT to in­ves­ti­gate its first di­ag­nos­tic test, AKRIV­IS GD, for ovar­i­an can­cer. The tri­al is re­cruit­ing across 20 US sites such as hos­pi­tals, gy­ne­col­o­gy and on­col­o­gy clin­ics, CEO Ori­ana Pa­pin-Zoghb told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.